Why Drug-Resistant Neonatal E. coli Meningitis Is Harder to Treat: Evidence of Dysregulated Host Signaling During Antibiotic Therapy
ACS Infectious Diseases · 16.11.2026
DOI: 10.1021/acsinfecdis.6c00213 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 16.11.2026. Verfasst von Yan Lei und 9 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Gefördert von: Yunnan High-level Health technical Personnel Training Program, Yunnan Young and Middle-aged Academic and Technical Leaders (reserve) Project, Yunnan High-level Personnel Training Program, Kunming "Chuncheng Plan" Training Project of High Level Talents.
Abstract (Originalsprache)
Treating neonatal meningitis caused by drug-resistant bacteria is clinically challenging. Conventional explanations focus on antibiotic failure, but whether infection with a drug-resistant clinical isolate is associated with altered host responses to therapy remains unknown. To compare host blood–brain barrier (BBB) responses to ampicillin plus Meropenem therapy in neonatal meningitis caused by standard versus drug-resistant Escherichia coli strains and to determine whether differences underlie treatment difficulty. Using standard and clinically isolated ampicillin/Meropenem-resistant E. coli, we established hCMEC/D3 cell and neonatal mouse meningitis models. Combination therapy effects on BBB function, tight junctions, ABC transporters, and signaling pathways were compared via TEER measurement, immunoblotting, and immunohistochemistry. In infection with the standard strain, therapy was associated with inhibition of PKC-α/RhoA and activation of PI3K/AKT/mTOR, alongside downregulation of BCRP, restoration of BBB function, and reduced neuroinflammation. In contrast, in infection with the drug-resistant clinical isolate, the same therapy only partially mitigated damage. This infection was accompanied by host signaling dysregulation, characterized by persistent PKC-α/RhoA activity, uncoordinated PI3K/AKT/mTOR activation, and compensatory MRP1 upregulation despite BCRP downregulation. The treatment difficulty of meningitis caused by the drug-resistant clinical isolate was associated with disrupted host signaling coordination during therapy, which may impair BBB repair. Combining antibiotics with host signaling modulators may improve outcomes.
Förderung
- Yunnan High-level Health technical Personnel Training Program
- Yunnan Young and Middle-aged Academic and Technical Leaders (reserve) Project
- Yunnan High-level Personnel Training Program, Kunming "Chuncheng Plan" Training Project of High Level Talents
- Yunnan Provincial Major Science and Technology Project in Biomedicine
- Yunnan International Science and Technology Co-Laboratory of Allergic Disease
- National Natural Science Foundation of China (NSFC)
- Yunnan Provincial Department of Science and Technology Plans Research Project
Zitieren
APA
Lei, Y., Zhou, Y., Liu, Y., Liu, X., Xiang, X., He, X., Wu, J., Chen, J., Li, Y., & Li, L. (2026). Why Drug-Resistant Neonatal E. coli Meningitis Is Harder to Treat: Evidence of Dysregulated Host Signaling During Antibiotic Therapy. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.6c00213
Vancouver
Lei Y, Zhou Y, Liu Y, Liu X, Xiang X, He X, et al. Why Drug-Resistant Neonatal E. coli Meningitis Is Harder to Treat: Evidence of Dysregulated Host Signaling During Antibiotic Therapy. ACS Infectious Diseases. 2026. doi:10.1021/acsinfecdis.6c00213
BibTeX
@article{Lei2026,
author = {Lei, Yan and Zhou, Yuantao and Liu, Yumiao and Liu, Xiaoning and Xiang, Xiaoyi and He, Xiaoli and Wu, Jiayuan and Chen, Jiyu and Li, Yangfang and Li, Li},
title = {Why Drug-Resistant Neonatal E. coli Meningitis Is Harder to Treat: Evidence of Dysregulated Host Signaling During Antibiotic Therapy},
journal = {ACS Infectious Diseases},
year = {2026},
doi = {10.1021/acsinfecdis.6c00213}
}
EUVIMED